Tobi Podhaler

This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.

Latest news

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised
NICE backs two cystic fibrosis treatments for NHS use

Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... The final draft guidance from the

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Competitive salary plus benefits

Account Manager – Healthcare advertising: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Client Services Director- Flexible Working: Negotiable

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...